Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care

Vita, Antonio; Deste, Giacomo; Barlati, Stefano; Peri, Luca De; Giambra, Agnese; Poli, Roberto; Keefe, Richard S.E.; Sacchetti, Emilio

doi:10.1016/j.schres.2013.02.035

Cited by 14 publications

(17 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The implication that SCoRS effectively evaluates functional outcome is consistent with previous studies (Chia et al, 2010, Keefe et al, 2006, Vita et al, 2013) using the Global Assessment Functioning (GAF) (Lehman, 1983), WHO-quality of life scale (The WHOQOL group, 1998), Health and the Nation Outcome Scale (HoNOS) (Wing et al, 1998), Independent Living Skills Inventory (ILSI) (Menditto et al, 1999), and University of California Performance-based Skills Assessment (UPSA) (Patterson et al, 2001) as a comparative measure. Results of the current study add to the concept that the SCoRS provides a valid measure of functional outcome in schizophrenia-spectrum disorders, including high-risk states.…”

Section: Discussionsupporting

confidence: 83%

“…Previous studies report performance on the BACS (Chia et al, 2010, Kaneda et al, 2011, Keefe et al, 2006) or Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) (Keefe et al, 2015) was significantly correlated with ratings with the SCoRS. Specifically, Vita et al (2013) found correlations between the interview's Global Rating Score on the SCoRS vs. processing speed, working memory and executive function (Vita et al, 2013). Overall, the results obtained in this study add to the concept that data from interview-based measures of cognition well reflect cognitive impairment as assessed by their performance-based counterparts.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies report the validity and reliability of SCoRS in other countries (Chia et al, 2010, Green et al, 2011, Harvey et al, 2011, Kaneda et al, 2011, Keefe et al, 2015, Keefe et al, 2006, Vita et al, 2013). The SCoRS was developed to measure cognitive functions through questions about cognitions related to daily life events (Keefe et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version

Higuchi

Sumiyoshi

et al. 2017

Schizophrenia Research: Cognition

View full text Add to dashboard Cite

Cognitive function is impaired in patients with schizophrenia-spectrum disorders, even in their prodromal stages. Specifically, the assessment of cognitive abilities related to daily-living functioning, or functional capacity, is important to predict long-term outcome. In this study, we sought to determine the validity of the Schizophrenia Cognition Rating Scale (SCoRS) Japanese version, an interview-based measure of cognition relevant to functional capacity (i.e. co-primary measure). For this purpose, we examined the relationship of SCoRS scores with performance on the Brief Assessment of Cognition in Schizophrenia (BACS) Japanese version, a standard neuropsychological test battery, and the Social and Occupational Functioning Assessment Scale (SOFAS), an interview-based social function scale.Subjects for this study (n = 294) included 38 patients with first episode schizophrenia (FES), 135 with chronic schizophrenia (CS), 102 with at-risk mental state (ARMS) and 19 with other psychiatric disorders with psychosis. SCoRS scores showed a significant relationship with SOFAS scores for the entire subjects. Also, performance on the BACS was significantly correlated with SCoRS scores. These associations were also noted within each diagnosis (FES, CS, ARMS).These results indicate the utility of SCoRS as a measure of functional capacity that is associated both with cognitive function and real-world functional outcome in subjects with schizophrenia-spectrum disorders.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version

Higuchi

Sumiyoshi

et al. 2017

Schizophrenia Research: Cognition

View full text Add to dashboard Cite

show abstract

“…The SCoRS has been used as a co-primary endpoint measure in several phase-2 and phase-3 trials assessing cognition in schizophrenia, and has been permitted by the FDA for pivotal registration trials. It also has exceptional test-retest reliability, strong relation to cognition, and a high sensitivity to treatment [104][105][106].…”

Section: Daily Functioningmentioning

confidence: 99%

Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia

Ospina

Wall

Jarskog

et al. 2019

J Psychiatry Brain Sci

View full text Add to dashboard Cite

Individuals with schizophrenia (SZ) display cognitive deficits that have been identified as major determinants of poor functioning and disability, representing a serious public health concern and an important target for interventions. At present, available treatments offer only minimal to moderate benefits to ameliorate cognitive deficits. Thus, there remains an urgent need to identify novel interventions to improve cognition in people with SZ. Emerging evidence from animal and basic human research suggests aerobic exercise training (AE) has beneficial effects on cognition. Preliminary findings suggest that AE is efficacious in improving cognitive functioning in SZ, however the extant studies have been limited by small samples, a dearth of information on biologically-relevant covariates, and limited information on impact on daily functioning. Additionally, while AE-related cognitive benefits have been linked to Brain-Derived Neurotrophic Factor (BDNF) upregulation, this putative mechanism needs

show abstract

“…The clinical stability criterion was based on positive symptoms due to their high impact on cognitive functioning assessment. The validity and applicability of SCoRS has been demonstrated in patients with clinical stable schizophrenia, but not in patients with a recent exacerbation of the illness and/or with significant positive symptomatology 14 . The Calgary Depression Scale (CDS) was used to assess depressive symptoms 15 .…”

Section: Clinical Cognitive and Quality Of Life Assessmentsmentioning

confidence: 99%

Toxoplasma gondii infection and chronic schizophrenia: is there any association?

Campos-Carli

Vieira

Rocha

et al. 2017

Arch. Clin. Psychiatry (São Paulo)

View full text Add to dashboard Cite

Background: Toxoplasma gondii (T. gondii) infection has been identified as a risk factor for schizophrenia. Objectives: Herein, we sought to evaluate the association between T. gondii infection and clinical symptoms and quality of life in patients with schizophrenia. Methods: We conducted a cross-sectional study with 48 patients with chronic schizophrenia and 40 controls. Peripheral blood was drawn, and IgM and IgG anti-T. gondii antibodies were evaluated by Enzyme-Linked Immunosorbent Assay (ELISA). Depressive, positive and negative symptoms were assessed, respectively, by the Calgary Depression Scale (CDS) and the Positive and Negative Syndrome Scale (PANSS). Cognitive performance was assessed in patients by the Brazilian version of the Schizophrenia Cognition Rating Scale (SCoRS-BR). Quality of life was assessed by the Brazilian version of the Quality of Life in Schizophrenia scale (QLS-BR). Results: The prevalence and titers of T. gondii IgM and IgG antibodies did not differ between patients and controls. The positive serology for T. gondii IgG antibodies was not associated with illness symptoms, cognitive performance, depressive symptoms or quality of life. Discussion: Our findings suggest that toxoplasmosis infection is not associated with severity of symptoms, quality of life, cognitive or depressive symptoms in schizophrenia patients.

show abstract

Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care

Cited by 14 publications

References 47 publications

Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version

Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version

Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia

Toxoplasma gondii infection and chronic schizophrenia: is there any association?

Contact Info

Product

Resources

About